[A summary: scaling up is difficult,
testing pharmacokinetics, toxicity and efficacy is difficult, and so is satisfying the FDA.]
Not exact matches
Although the small company I worked for did not conduct animal
testing on site, my work in drug discovery and providing analytical support to pharmacology directly linked me to the
pharmacokinetic and toxicology screening
tests.
Establish infrastructure to
test repurposed drugs in cell culture and animal models for potency,
pharmacokinetic (PK), and pharmacodynamic (PD) studies.
Because the long - term use of VPA in the clinical setting amassed
pharmacokinetics and safety data, it is rational to
test VPA in allogeneic BMT patients in combination with standard GVHD prophylaxis or treatment.